Solventum (FRA:KB7) Other Long-Term Liabilities: €422 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KB7 Solventum Corp FRA:KB7
30 GF Score
Price €73.80
! 7 Warning Signs
View Full Analysis

What is Solventum Other Long-Term Liabilities?

Solventum FRA:KB7 -1.10% 30 Other Long-Term Liabilities is €422 Mil as of Jun. 2026. GuruFocus rates FRA:KB7 with a GF Score™ of 30/100. The stock has 7 warning signs investors should review.

Solventum's other long-term liabilities for the quarter that ended in Jun. 2026 was €422 Mil.

Solventum's quarterly other long-term liabilities declined from Dec. 2025 (€466 Mil) to Mar. 2026 (€413 Mil) but then increased from Mar. 2026 (€413 Mil) to Jun. 2026 (€422 Mil).

Solventum's annual other long-term liabilities increased from Dec. 2023 (€139 Mil) to Dec. 2024 (€392 Mil) and increased from Dec. 2024 (€392 Mil) to Dec. 2025 (€466 Mil).

Solventum Other Long-Term Liabilities Related Terms

Solventum Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Solventum's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solventum Other Long-Term Liabilities Chart

Solventum Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial 216.83 221.84 139.38 391.55 466.28

Solventum Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 354.60 372.32 466.28 413.47 421.85
FRA:KB7
30GF Score
Solventum Corp FRA:KB7
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solventum Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €422 Mil mean?
Solventum (FRA:KB7) has a Other Long-Term Liabilities of €422 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Solventum and its competitors.
Is Solventum's Other Long-Term Liabilities too high?
Solventum's current Other Long-Term Liabilities is €422 Mil. Overall, Solventum has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Solventum's Other Long-Term Liabilities compare to COO and ALGN?
Solventum's Other Long-Term Liabilities of €422 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Devices & Instruments company?
A good Other Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Solventum and its competitors. Solventum's current Other Long-Term Liabilities is €422 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solventum stock overvalued right now?
Solventum (FRA:KB7) has a current Other Long-Term Liabilities of €422 Mil. The current Other Long-Term Liabilities is €422 Mil. Solventum's overall GF Score™ is 30/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Solventum (FRA:KB7), the current Other Long-Term Liabilities is €422 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solventum Business Description

Address 2510 Conway Avenue East, 3M Center, Building 275-6W, Maplewood, MN, USA, 55144
Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which earns maximum revenue and provides wound therapy, I.V. site management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and OEM medical technologies; Dental Solutions, offering dental and orthodontic products such as brackets, restorative cements, and bonding agents; and Health Information Systems, providing software solutions including physician documentation, coding automation, speech recognition, and data visualization platforms. It operates in the United States, which earns the majority of revenue, and internationally.
30GF Score

Get the complete analysis for FRA:KB7

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€73.80
Price